Eton Pharmaceuticals Gains FDA Approval for DESMODA and Raises 2026 Revenue Guidance to $120 Million

Eton Pharmaceuticals' Q1 2026 results signal a rare disease portfolio executing across multiple regulatory and commercial fronts simultaneously, with FDA approval and launch of DESMODA, the first oral desmopressin solution, anchoring a quarter that posted $24.3 million in product sales, up 73% year-over-year.

For QA directors and regulatory leads tracking orphan drug pathways, the DESMODA launch is the most operationally significant data point. The product cleared FDA review and entered commercial distribution within the same quarter, a compressed timeline that reflects the agency's continued prioritisation of rare disease formulations with unmet need. Separately, Eton received FDA clearance to proceed with an INCRELEX label harmonization study, scheduled to initiate later in 2026, adding a concurrent regulatory workload that will require disciplined post-approval change management under ICH Q10 principles.

The relaunch of HEMANGEOL on May 1 introduced a distribution model shift worth noting for supply chain and commercial operations leads. Eton moved the product to a high-touch, rare disease-focused distribution structure, consolidating patient access under its Eton Cares programme, which includes zero co-pay provisions for qualifying commercial patients. Early transition metrics from providers and care teams are reported as stable, though the relaunch remains in its initial weeks.

Pipeline activity adds further regulatory complexity to the near-term calendar. Eton initiated a clinical study for the KHINDIVI label expansion and launched a pilot study for ET-700, an extended-release zinc acetate formulation. Running two active clinical programmes alongside two commercial launches and a pending label harmonization study represents a material increase in GMP and regulatory affairs resource demands for an organisation of Eton's scale.

Full-year 2026 revenue guidance has been raised to exceed $120 million, up from the prior $110 million target, with DESMODA and HEMANGEOL cited as primary incremental contributors through 2026 and 2027.

The INCRELEX label harmonization study initiation, expected later in 2026, will serve as a near-term checkpoint for how Eton manages concurrent post-approval regulatory commitments across an expanding rare disease portfolio.

Source: Eton Pharmaceuticals via GlobeNewswire, May 14, 2026. Management conference call held same day at 4:30 PM ET.